Sensitivity and proportionality assessment of metabolites from microdose to high dose in rats using LC-MS/MS.

BACKGROUND The objective of this study was to evaluate the sensitivity requirement for LC-MS/MS as an analytical tool to characterize metabolites in plasma and urine at microdoses in rats and to investigate proportionality of metabolite exposure from a microdose of 1.67 µg/kg to a high dose of 5000 µg/kg for atorvastatin, ofloxacin, omeprazole and tamoxifen. RESULTS Only the glucuronide metabolite of ofloxacin, the hydroxylation metabolite of omeprazole and the hydration metabolite of tamoxifen were characterized in rat plasma at microdose by LC-MS/MS. The exposure of detected metabolites of omeprazole and tamoxifen appeared to increase in a nonproportional manner with increasing doses. Exposure of ortho- and para-hydroxyatorvastatin, but not atorvastatin and lactone, increased proportionally with increasing doses. CONCLUSION LC-MS/MS has demonstrated its usefulness for detecting and characterizing the major metabolites in plasma and urine at microdosing levels in rats. The exposure of metabolites at microdose could not simply be used to predict their exposure at higher doses.

[1]  R. C. Garner,et al.  A pharmacokinetic evaluation of five H(1) antagonists after an oral and intravenous microdose to human subjects. , 2009, British journal of clinical pharmacology.

[2]  Tomio Inoue,et al.  Accelerator mass spectrometry analysis of background 14C-concentrations in human blood: aiming at reference data for further microdosing studies , 2008, Annals of nuclear medicine.

[3]  R. Colin Garner,et al.  The utility of microdosing over the past 5 years , 2008, Expert opinion on drug metabolism & toxicology.

[4]  Jon L Ruckle,et al.  Use of accelerator mass spectrometry to measure the pharmacokinetics and peripheral blood mononuclear cell concentrations of zidovudine. , 2008, Journal of pharmaceutical sciences.

[5]  H. Ouyang,et al.  Microdosing Assessment to Evaluate Pharmacokinetics and Drug Metabolism in Rats Using Liquid Chromatography-Tandem Mass Spectrometry , 2008, Pharmaceutical Research.

[6]  Yuichi Sugiyama,et al.  Microdose clinical trial: quantitative determination of fexofenadine in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[7]  M. Hoffmann,et al.  DFT study on hydroxy acid-lactone interconversion of statins: The case of fluvastatin. , 2006, Organic & biomolecular chemistry.

[8]  M. Lee,et al.  Pharmacokinetics of omeprazole in rats with water deprivation for 72 hours , 2006, Biopharmaceutics & drug disposition.

[9]  Malcolm Rowland,et al.  Use of microdosing to predict pharmacokinetics at the therapeutic dose: Experience with 5 drugs , 2006, Clinical pharmacology and therapeutics.

[10]  Sang-Chul Shin,et al.  Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats. , 2006, International journal of pharmaceutics.

[11]  Hua Yang,et al.  EVALUATION OF MICRODOSING TO ASSESS PHARMACOKINETIC LINEARITY IN RATS USING LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY , 2006, Drug Metabolism and Disposition.

[12]  R. Subramanian,et al.  ACYL-COENZYME A FORMATION OF SIMVASTATIN IN MOUSE LIVER PREPARATIONS , 2006, Drug Metabolism and Disposition.

[13]  R. C. Garner,et al.  The use of accelerator mass spectrometry to obtain early human ADME/PK data , 2005, Expert opinion on drug metabolism & toxicology.

[14]  R Colin Garner,et al.  Less is more: the human microdosing concept. , 2005, Drug discovery today.

[15]  M. P. Baker,et al.  EVALUATION OF MICRODOSING STRATEGIES FOR STUDIES IN PRECLINICAL DRUG DEVELOPMENT: DEMONSTRATION OF LINEAR PHARMACOKINETICS IN DOGS OF A NUCLEOSIDE ANALOG OVER A 50-FOLD DOSE RANGE , 2004, Drug Metabolism and Disposition.

[16]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[17]  R. Colin Garner,et al.  Big physics, small doses: the use of AMS and PET in human microdosing of development drugs , 2003, Nature Reviews Drug Discovery.

[18]  H. Cai,et al.  Regulation of CYP2B6 and CYP3A expression by hydroxymethylglutaryl coenzyme A inhibitors in primary cultured human hepatocytes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[19]  B. Ma,et al.  Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[20]  G. Grass,et al.  Physiologically-based pharmacokinetic simulation modelling. , 2002, Advanced drug delivery reviews.

[21]  Thomayant Prueksaritanont,et al.  β-Oxidation of Simvastatin in Mouse Liver Preparations , 2001 .

[22]  I Mahmood,et al.  Allometric issues in drug development. , 1999, Journal of pharmaceutical sciences.

[23]  B. Roth,et al.  Metabolism and excretion of atorvastatin in rats and dogs. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[24]  M. Radtke,et al.  Biotransformation of cerivastatin in mice, rats, and dogs in vivo. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[25]  P. Neuvonen,et al.  Effect of itraconazole on the pharmacokinetics of atorvastatin , 1998, Clinical pharmacology and therapeutics.

[26]  D J Rance,et al.  The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. , 1997, The Journal of pharmacology and experimental therapeutics.

[27]  M. Rowlands,et al.  Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[28]  D. Hunninghake,et al.  Biotransformation of lovastatin. V. Species differences in in vivo metabolite profiles of mouse, rat, dog, and human. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[29]  F. Wong,et al.  The metabolism of ofloxacin in humans. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[30]  K. Hoffmann.  Identification of the main urinary metabolites of omeprazole after an oral dose to rats and dogs. , 1986, Drug metabolism and disposition: the biological fate of chemicals.

[31]  J. Fromson,et al.  The metabolism of tamoxifen (I.C.I. 46,474). I. In laboratory animals. , 1973, Xenobiotica; the fate of foreign compounds in biological systems.

[32]  Toshihiko Ikeda,et al.  Use of an intravenous microdose of 14C-labeled drug and accelerator mass spectrometry to measure absolute oral bioavailability in dogs; cross-comparison of assay methods by accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry. , 2009, Drug metabolism and pharmacokinetics.

[33]  K. Sudo.  Microdosing for reduction of the time and resources for drug development. , 2007, Drug metabolism and pharmacokinetics.

[34]  Italo Poggesi,et al.  Predicting human pharmacokinetics from preclinical data. , 2004, Current opinion in drug discovery & development.

[35]  H. Lennernäs.  Clinical Pharmacokinetics of Atorvastatin , 2003, Clinical pharmacokinetics.

[36]  G. Grass.  Physiologically-based pharmacokinetic simulation modeling , 2002 .

[37]  K. Hoffmann,et al.  Identification of two main urinary metabolites of [14C]omeprazole in humans. , 1989, Drug metabolism and disposition: the biological fate of chemicals.

[38]  K. Sudo,et al.  Isolation and identification of metabolites of ofloxacin in rats, dogs and monkeys. , 1986, Xenobiotica; the fate of foreign compounds in biological systems.

[39]  J. Fromson,et al.  The Metabolism of Tamoxifen (I.C.I. 46,474) Part II: In Female Patients , 1973 .